logo-loader
viewCytoDyn

Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases to liver and lung in preclinical study

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive its flagship drug leronlimab inhibited a human colon carcinoma cell line metastases to liver and lung in a well-accepted mouse model.

Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket trial, including most of the cancer with CCR5 indicators.

Quick facts: CytoDyn

Price: 0.286 USD

OTCMKTS:CYDY
Market: OTCMKTS
Market Cap: $111.04 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals positive data on metastatic triple-negative...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive it has released additional early Phase 1b/2 clinical trial results of its lead drug leronlimab in patients with CCR5 metastatic triple-negative breast cancer. Pourhassan says representatives from its lab called him crying, revealing...

2 days, 17 hours ago

2 min read